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Introduction: Stereotactic ablative body radiotherapy (SABR) provides a superior non-
small cell lung cancer (NSCLC) treatment option when compared to conventional radio-
therapy for patients deemed inoperable or refusing surgery. This study retrospectively
analyzed the rates of tumor control and toxicity following SABR treatment (Cyberknife
system) of primary early-stage NSCLC in a community setting.
Methods: One hundred patients were treated between 2007 and 2011. Patients with
T3-4 or N1-3 disease, metastasis, recurrent local disease, or a non-lung primary were
excluded from analysis. All patients had biopsy proven disease. Staging included CT
or fluorodeoxyglucose-positron emission tomography scan. Median dose was 54Gy
(45–60); 18Gy (10–20) per fraction. Median planned target volume expansion was 8mm
(2–10). Median BED was 151.2. Tumors were tracked via Synchrony, X-Sight Lung, or
X-Sight Spine. Patients were evaluated for local control, overall survival (OS), and toxicity.
All local failures were determined by evaluating post treatment PET/CT.
Results:With amedian follow up of 27.5months, the 1-, 2-, and 3-year local control rates
were 100, 93.55, and 84.33%, respectively. Median survival was 2.29 years; actuarial 3-
year survival was 37.20%. Grade-3 toxicity was observed in 2% of patients (pneumonia
within 2months of treatment, n=1; chronic pneumonitis requiring hospital admission,
n=1). No patients demonstrated toxicity above Grade-3. Multivariate analysis did not
show T-stage as an independent predictor of OS, though it did trend toward significance.
Conclusion: In a community-center setting, definitive treatment of NSCLC with SABR for
non-surgical candidates and those who choose to forego surgery result in excellent and
comparable rates of local control and toxicity compared to published series from large
academic centers.
Keywords: cyberknife, non-small cell lung cancer, stereotactic body radiotherapy, stereotactic ablative radiother-
apy, radiation oncology, XSight, radiation toxicity, early-stage lung cancer
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Introduction
Since the report of the initial experience from Indiana Univer-
sity regarding the use of stereotactic ablative body radiotherapy
(SABR) for early-stage non-small cell lung cancer (NSCLC) (1),
there has been an explosion of interest and utility of this type of
treatment. This formof treatment gives patientswho are otherwise
inoperable a new option with results that are generally superior
to conventional radiotherapy (2). Operable patients who refuse
surgery now also have this treatment alternative available (3–5).
While many reports have come from large academic institutions,
experiences at community hospital based centers are lacking. The
need for more data from these centers is underscored as rapidly
increasing numbers of community based centers are using SABR
for the treatment of NSCLC.
The primary purpose of this study is to retrospectively inves-
tigate the rates of tumor control and toxicities related to the use
of SABR in the treatment of primary early-stage NSCLC in a
community center setting. The secondary purpose is to investigate
potential tumor control differences using different techniques of
planning and treatment delivery.
Materials and Methods
Between January 2007 and August 2011, 100 patients who under-
went definitive SABR at the Philadelphia CyberKnife for a stage
I–II NSCLC were retrospectively reviewed from our patient
database after receiving institutional review board approval
(CKHS 14-006). Patients with T3–4 or N1–3 diseases, metastasis,
small cell histology, absence of biopsy, recurrent disease, or a non-
lung primary were excluded from the analysis. Patients included
those deemed: (a) inoperable – based on pulmonary function
tests, i.e., forced expiratory volume in 1 s (FEV1)<50% predicted
or diffusing capacity of lung for carbon monoxide (DLCO) of
<50% predicted, comorbidities, and recommendations from a
multidisciplinary tumor board that included participation from
radiation oncology, thoracic surgery, and medical oncology, as
well as (b) operable ones who refused surgery.
All patients had biopsy proven disease. Staging was done with
CT scanning and fluorodeoxyglucose-positron emission tomog-
raphy (FDG-PET). All mediastinal staging were based on FDG-
PET results.
Patients were treated on the CyberKnife® stereotactic radiation
therapy system (Accuray, Sunnyvale, CA, USA). Tumor tracking
was accomplishedwith one of threemethods: (a) fiducial tracking,
(b) X-Sight Lung, which tracks the tumor directly, and (c) X-
Sight Spine, which tracks a nearby vertebral body. CT simulation
was done with three scans: regular inspiratory breath hold CT,
expiratory breath hold, and free breathing CT. The expiratory
hold CT was used for dosimetry calculation purpose. Contours
were made on the MulitPlan® planning system. In case of fiducial
and X-Sight Lung tracking, only the expiratory breath hold scan
was contoured to define the gross tumor volume (GTV) with
planned target volume (PTV) generated by an 5–8mm expansion.
Using X-Sight Spine, all three phases were contoured to define
the internal target volume (ITV), and the PTV was generated
using a 5mm expansion. Fractionation was determined using a
risk adapted approach depending on tumor size and location. In
general, patients with a peripheral tumor were treated to a dose
of 60Gy in 3 fractions before heterogeneity was accounted for,
and 54Gy in 3 fractions once we started using the Monte Carlo
advanced dosimetry algorithm. Patients with a central tumor
received 50Gy (10Gy 5 fractions or 12.5Gy 4 fractions). The
dosimetry algorithmusedwas Ray Tracing from2007 to 2011, and
then Monte Carlo from June 2011.
The first follow-up visit was typically at 1month post-
treatment, then every 3–4months for 1 year, and annually
thereafter. Follow-upCT scanswere performed at each visit. FDG-
PET scans were repeated at the managing physician’s discretion
especially in cases where a growing lesion on CT could not be
differentiated from tumor growth or fibrosis. Treatment response
measurements were adopted from RECIST v1.1 (http://imaging.
cancer.gov/clinicaltrials/imaging). Toxicity was scored based on
the CTCAE v4 guidelines (6).
Local control (LC) is defined as the absence local failure. Local
failure is defined either as primary tumor failure (PTF), marginal
failure (MF) (within 1 cm of the PTV), or involved lobe failure
(ILF). Regional failure is defined as failure in the regional lymph
nodes. Distant failure is defined as failure outside of the local and
regional areas.
Kaplan–Meier methodology was used to estimate outcomes
of survival and LC, with comparisons accomplished using the
log–rank statistics. Cox proportional hazards modeling was used
to assess univariate andmultivariable predictors of outcome. Final
multivariable models were the result of building a full model com-
prised of all variables demonstrating significance at the 0.20 level
on univariate analysis, followed by sequential elimination of the
least significant variable until only those remaining in the model
demonstrate significance at the 0.10 level. Statistical significance
is concluded on the basis of a two-tailed p-value of 0.05.
Results
From January 2007 to August 2011, 100 patient records with
a median follow up of 27.5months (range: 2–77months) were
analyzed. The median age at treatment was 75 years. Tumors were
classified as centrally (27%) or peripherally (73%) located. Patient
characteristics are summarized in Table 1.
The median survival was 2.29 years and the 3-year overall sur-
vival (OS)was 37% (Figure 1). The Kaplan–Meier LC at 1-, 2-, and
3 years is 100, 94, and 84%, respectively (Figure 2). A total of 40
patients had cancer recurrence. The pattern of relapse included
six local failures (4 PTF, 0 MF, and 2 ILF), 26 regional failures,
and 20 distant failures. Of the T1 and T2 patients, 18 (28.6%) and
10 (27.0%) had regional failures, respectively. Distributions of the
pattern of relapse are shown in Figure 3. The pattern of recurrence
with 3 local only failures, 14 regional only failures, 9 distant only
failures, 11 regional and distant failures, and 3 local, regional, and
distant failures.
About 48% of patients were treated with fiducial tracking, 26%
with X-sight Lung, and 26% with X-sight Spine. Of the six local
failures, three were tracked using gold fiducials, two were tracked
using X-Sight Spine, and one was tracked using X-Sight Lung.
About 80%patientswere plannedwith theRayTracking algorithm
and 20% were with the Monte Carlo algorithm. No meaningful
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TABLE 1 | Patient Characteristics.
Patient Characteristics Number of Patients
Median Age (years) 75 (60–88)
Gender
Male 53
Female 47
Location
Central 27
Peripheral 73
Specific Path
Adenocarcinoma 33
Squamous Cell 40
Large 2
NSCLC-NOS 25
Stage
T1 63
T2 37
Tumor Size Median (cm) 2.6
FIGURE 1 | Overall Survival.
correlation of LC could be made between the two algorithms with
only six local failures.
The median tumor size and PET SUV before treatment were
2.60 cm and 5.90mg/mL, respectively. The most recent PET/CT
of patients after treatment revealed a median tumor size and
activity of 1.98 cm and 2.40mg/mL, respectively. Other treatment
characteristics are summarized in Table 2.
The data from the univariate analysis are shown inTable 3. The
resulting multivariate analysis showed neither T-stage nor BED
as an independent predictor of OS (Table 4). However, T-stage
did show a strong trend toward predictive value. No meaningful
covariate analysis could be made with regard to LC due to the low
number of events.
Acute and chronic toxicities were evaluated in four categories:
lung, esophagus, skin, and pain. Of 100 patients studied, two had
toxicities scored at Grade 3 or above. They were Grade 3 toxicities
for acute lung (1–90 days) due to acquiring pneumonia within
2months of treatment (n= 1) and for chronic lung (>90 days)
after acquiring chronic pneumonitis requiring hospital admission
FIGURE 2 | Local Control.
FIGURE 3 | Pattern of Failure.
TABLE 2 | Treatment Characteristics.
Treatment Characteristics Median Range SD
BED dose (Gy10) 151 100–180 32.5
Prescription dose (Gy) 54 45–60 4.82
PTV margin (mm) 8 2–10 1.68
PTV volume (cm3) 34.4 8.3 117.9
Number of beams 107 42 207
Isodose line 70 60–84 5.4
(n= 1). There were no acute or chronic Grade 3 toxicities for
esophagus, skin, or pain, and no toxicities Grade 4 or above in
any category (Table 5).
Discussion
There has been a rapid rise in the use of SABR for the definitive
treatment of primary early-stage NSCLC for inoperable patients
Frontiers in Oncology | www.frontiersin.org June 2015 | Volume 5 | Article 1463
Heal et al. Community SABR for inoperable NSCLC
TABLE 3 | Univariate Analysis.
Parameter Frequency (%) Hazard
Ratio
95% Confidence
Limit
p-Value
T-Stage
T1 63 0.54 0.36–0.94 0.0267
T2 37 1.00
Gender
Female 53 1.05 0.66–1.67 0.8280
Male 47 1.00
Location
Central 27 0.74 0.43–1.28 0.2875
Peripheral 73 1.00
Histology
Adenocarcinoma 33 1.01 0.57–1.78 0.9707
Large cell 2 3.20 0.74–13.77 0.1183
NSCLC-NOS 25 0.94 0.51–7.50 0.8269
Squamous cell 40 1.00
Tumor Tracking
Fiducials 48 0.92 0.516–1.64 0.7771
X-Sight Lung 26 1.22 0.64–2.33 0.5474
X-Sight Spine 26 1.00
Dose Algorithm
Monte Carlo 20 1.53 0.83–2.74 0.1538
Ray Tracing 80 1.00
Plan Centricity
Isocentric 65 1.07 0.66–1.76 0.7817
Non-isocentric 35 1.00
Number of Fractions
3 62 2.50 0.98–6.32 0.0537
4 25 3.39 1.28–8.98 0.0139
5 13 1.00
BED Stratified
100–110Gy 15 0.60 0.28–1.28 0.1836
111–120Gy 25 1.26 0.74–2.15 0.4025
>120Gy 60 1.00
PTV Margin – 0.94 – 0.3989
Age – 1.03 0.0617
TABLE 4 |Multivariate analysis.
Parameter Hazard
Ratio
95% Confidence
Limits
p-Value
T-Stage
T1 0.62 0.36–1.05 0.0737
T2 1.00
BED Stratified
100–110Gy 0.50 0.22–1.12 0.0908
111–120Gy 1.21 0.68–2.15 0.5114
>120Gy 1.00
since the publication of the initial Indiana experience (7). Since
then, more data have emerged that further substantiate the utility
of this treatment method as an emerging standard of care for the
inoperable patient population (8). There is, however, a paucity
of published data from community-based cancer centers, which
accounts for a significant part of this increase in utility.
To our knowledge, this is the largest series that has looked at
this treatment modality in a community-based cancer center. Our
TABLE 5 | Acute and Chronic Toxicity Grading.
Grade 1–2 Grade 3 Grade 4–5
Acute lung 13 1a 0
Chronic lung 10 1a 0
Acute esophagus 4 0 0
Chronic esophagus 1 0 0
Acute skin 1 0 0
Chronic skin 0 0 0
Pain 9 0 0
Rib fracture 1 0 0
aOne patient with pneumonia within 2months of treatment; one patient with chronic
pneumonitis requiring hospitalization.
results show a 3-year LC and OS that is in-line with the published
series from large academic institutions (Table 6).
Compared to the pattern of relapse from the long-term update
of RTOG0236 (12), where the 5-year regional and distant progres-
sion are 38 and 31%, respectively, our results also demonstrated a
large percentage of patients who experienced regional or distant
failure (26 and 20%, respectively).
We reason that our reliance on PET as the primary staging
method, while non-invasive, may underestimate the degree of
regional lymph node involvement at the time of initial diagnosis,
therefore giving way to increase in regional nodal failure. While
mediastinoscopy staging is the gold standard, performing invasive
mediastinal biopsies carries a risk to any patient, andmay not even
be possible for inoperable patients with significantly decreased
pulmonary function. This dilemma highlights the potential utility
of minimally invasive endobronchial ultrasound-guided trans-
bronchial needle biopsy to evaluate hilar and mediastinal lymph
nodes as a part of the staging work up (13).
With regards to the high rate of distant progression, this may
be due to the presence of circulating tumor cells (CTC) that have
already seeded or have the potential to seed locations outside the
original tumor area (14–16). Even if a curative dose of radiation
therapy is administered at the tumor site, other areas of the lung
and organs are left untreated, which raises the important question
of whether the number of CTC or the characteristics of these CTC
(isolated vs. clustered) will predict for a greater role of adjuvant
chemotherapy to prevent distant progression.
With regards to toxicity, our experience shows a favorable
toxicity profile of having 2% Grade 3 toxicity, and no grade 4 or
5 toxicity. One reason for this may be due to our risk adaptive
approach, as guided by other experiences (11, 17–19), in which
central tumors and tumors close to other critical structures would
receive amore fractionated regimen of 4–5 fractions, in an attempt
to deliver a more tolerable dose to the normal tissue, but at
the same time a potent enough dose of BED >100Gy10 to the
tumor (4, 20). Another reason could be due to technological
improvements over time. Our ability to track the tumor through-
out treatment in real-timewithCyberKnifemay improve accuracy
of treatment, allowing for smaller PTV margins. This leads to
less overall toxicity, while maintaining a comparable rate of LC.
Others have also reported excellent toxicity data using real-time
tracking (21).
Regarding covariate of treatment planning and delivery, neither
algorithm or dose nor PTV margin was significant in predicting
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TABLE 6 | Comparable Publications.
Author N Median F/U
(months)
Median BED (Gy10) 3-year LC (%) 3-year OS (%)
Onishi et. al (9) 245 24 108 85 40
Baumann et. al (10) 138 33 112.5 (15Gy3) 88 52
Timmerman et. al (11) 70 32 180 (151a) 88 42
Present Study 100 27 151 84 37
aHeterogeneity correction equivalent.
OS. During the study period, although the Ray Tracing algo-
rithm was used 80% of the time, some of these plans were
started with Ray Tracing but were then compared to a Monte
Carlo estimate. This was done to leverage the efficiency of Ray
Tracing, while keeping Monte Carlo as a gold standard. In gen-
eral, Monte Carlo was used as a comparison for small tumors
where there is inadequate dose build up due to tissue hetero-
geneity. If there was no significant difference between the esti-
mates, then the Ray Tracing plan was executed. As of June
2011, all treatments were planned and executed using the Monte
Carlo algorithm. Others have reported a dose–response relation-
ship (17). While a dose–response relationship was not noted
due to small number of local failures, we have demonstrated
previously that Ray Tracing can significantly underdose small
tumors by as much as 30–40% (22), and has been supported
by others (23). We further postulate that even if there exists
a dose–response relationship, that this difference may be too
small to detect since all of our prescriptions have been given
in a range above BED>100Gy10 where there is evidence to
suggest that a dose plateau may occur starting around 100Gy
BED (24, 25).
T-stage showed a strong trend toward being an independent
prognostic factor for OS. This raises the hypothesis of whether
using neoadjuvant chemotherapy to initially downstage the tumor
before SABR, or using chemotherapy in the adjuvant setting will
provide any additional benefit in patients with larger tumors. BED
showed no independent predictive value related to OS. Again, this
is likely due to the relatively high BED prescription (>100Gy)
and curative approach to treatment. It is interesting to note that a
recent report found a survival benefit of using a prescription BED
>150Gy in patients with T2 tumors (26). In our study, the number
of fractionswas not included in the finalmultivariatemodel due to
its high correlation with BED and the possibility of confounding
the data.
Limitations of this study include the retrospective nature of this
analysis. This may also give way to under reporting of toxicity.
Although each patient chart was reviewed using the CTCAE
v4.0 reporting criteria for toxicity, lack of a central review or
definitive protocol during treatment allowed for physician bias
when symptoms were entered into the medical record. Size is
another limitation of this study. Although this study evaluated 100
patients, having only six local failures limits the ability to study
potential correlations between LC and other covariates such as
various methods of tumor tracking.
Conclusion
Stereotactic ablative body radiotherapy for the definitive treat-
ment of early-stage inoperable NSCLC in the community cancer
center setting has a LC and OS rate that is comparable to large
academic institutions. Our risk adaptive approach of using the
appropriate fractionated schedule based on tumor location and
proximity to critical structures may explain for a very favorable
toxicity profile. Future studies on CTC may identify patients with
a high risk of distant progression and predict for the benefit of
systemic therapy.
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